我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

莫雷西嗪合用倍他乐克治疗良性室性早搏的疗效和安全性(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2004年第3期
页码:
268-269
栏目:
临床研究
出版日期:
2004-05-01

文章信息/Info

Title:
The efficacy and safety of Moricizine combinated Betalac in benign ventricular ectopic beats
作者:
章耀
温州市第二人民医院，浙江 温州 325000
Author(s):
ZHANG Yao
Department of Cardiology，Wenzhou Second People’s Hospital，Wenzhou，Zhejiang 325000 China
关键词:
莫雷西嗪; 倍他乐克; 早搏; 室性
Keywords:
Moricizine; Batalac; ectopic beat; ventricular
分类号:
R541.7
DOI:
-
文献标识码:
A
摘要:
目的:评价莫雷西嗪合用倍他乐克治疗良性室性期前收缩(室早)的疗效和安全性。方法:选择80例无器质性心脏病变的良性室早患者，随机分为两组，38例为莫雷西嗪组(单用组),42例为莫雷西嗪合用倍他乐克组(合用组)。分析两组的疗效和不良反应。结果:单用组和合用组治疗良性室早的有效率分别为74%和81%，不良反应发生率分别为37%和33%，两组间均无显著性差异。结论:莫雷西嗪合用倍他乐克是治疗良性室早的一种安全、有效的方法。
Abstract:
AIM:To evaluate efficacy and safety of Moricizine combinated Batalac in benign ventricular ectopic beats.:METHODS:80 patients with benign ventricular ectopic beats，without structural heart disease were randomly divided into two groups，among whom 38 were assigned to Moricizine group (single group) and 42 to Moricizine combinated Batalac group (combinated group).To analyse effective rate and occurrence rate of adverse reaction in the two groups. RESULTS: The effective rate of single group and combinated group were 74%，81%;the occurrence rate of adverse reaction of single group and combinated group were 37%，33%，respectively. There were no significant difference between the two groups. CONCLUSION:This study demonstrates that Moricizine combinated Batalac is efficent and safe in benign ventricular ectopic beats.

参考文献/References

[1] Epstein AE, Bigger JT, Wyse DG, et al.Events in the cardiac arrhythmia suppression trial(CAST):Mortailty in the entriepopulation enrolled[J].d Am CollC ardio1,1991,18:14-19.

[2] 诸骏仁，李志善，陶萍，等.普罗帕酮、莫雷西嗪、美西律的疗效和安全性再评价[J].中华心血管病杂志,1998,3:168-174.

[3] 徐有秋.心律失常的心肌电生理研究进展[J].心脏杂志,2003,15(2):165-168.

[4] 徐有秋.抗心律失常药物和离子通道[J].心脏杂志，2001,13(2):143-145.

备注/Memo

备注/Memo:
收稿日期：2003-4-4
更新日期/Last Update: 2004-05-01